Regulatory News:
ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.
Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th, 2024:
245,176 shares
- 252,168.60
- Number of executions on buy side on semester: 990
- Number of executions on sell side on semester: 956
- Traded volume on buy side on semester: 504,480 shares for 524,812.30
- Traded volume on sell side on semester: 324,426 shares for 473,133.44
As a reminder:
- the following resources appeared on the last half year statement on 31 December 2023 on the liquidity account:
65,122 shares
- 299,098.61
- Number of executions on buy side on semester: 340
- Number of executions on sell side on semester: 227
- Traded volume on buy side on semester: 39,590 shares for 173,764.12
- Traded volume on sell side on semester: 17,891 shares for 85,132.33
- the following resources appeared on the liquidity account when the activity started:
0 shares
- 600,000.00
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.
About ACTICOR BIOTECH
Acticor Biotech is a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, particularly ischemic stroke.
The positive results of the phase 1b/2a study, ACTIMIS, published in January 2024 in the Lancet Neurology (link to publication) confirmed the safety profile of glenzocimab and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group of stroke patients. A post-hoc analysis of brain imaging at 0 and 24 hours using artificial intelligence confirmed these results, showing a reduction in the number and volume of intracerebral lesions in patients treated with glenzocimab.
On April 25, 2024, the company announced the initial results of the international phase 2/3 ACTISAVE study in the treatment of acute ischemic stroke, which showed no efficacy of glenzocimab on the primary endpoint, the proportion of patients with severe disability or death (mRS 4-6) 90 days after stroke, nor on the secondary endpoint, the proportion of patients returning to life without disability (mRS 0-2).
On May 15, 2024, Prof. Martin Köhrmann (Principal Investigator of ACTISAVE) presented the main results of the study at the opening session of the European Stroke Organization Conference (ESOC), confirming the neutrality of the study on the primary and secondary endpoints, and showing trends in return to normal life (mRS 0-1), notably in sub-populations of patients with complete recanalization after mechanical thrombectomy.
Glenzocimab is being evaluated in 2 other clinical trials initiated by academic teams:
- GREEN: a phase 2/3 study in the treatment of stroke in thrombectomized patients, with a futility analysis after inclusion of the first 78 patients (30% of patients) expected in Q4 2024;
- LIBERATE: a Phase 2b LIBERATE trial in the treatment of myocardial infarction, with final results expected in Q4 2025.
Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation) and has been listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 ALACT).
For more information, visit: www.acticor-biotech.com
Buy Side | Sell Side | ||||||
Number of
| Number of
| Traded volume in
| Number of
| Number of
| Traded volume in
| ||
Total | 990 | 504,480 | 524,812.30 | 956 | 324,426 | 473,133.44 | |
02/01/2024 | 1 | 250 | 725.00 | 2 | 250 | 737.50 | |
05/01/2024 | 3 | 251 | 740.45 | 1 | 1 | 2.97 | |
08/01/2024 | 8 | 750 | 2,257.50 | ||||
09/01/2024 | 5 | 675 | 2,112.75 | ||||
10/01/2024 | 1 | 100 | 306.00 | 3 | 25 | 79.00 | |
11/01/2024 | 6 | 901 | 2,703.00 | 3 | 251 | 778.10 | |
12/01/2024 | 6 | 1,223 | 3,510.01 | 4 | 501 | 1,477.95 | |
15/01/2024 | 5 | 500 | 1,435.00 | 4 | 159 | 457.92 | |
16/01/2024 | 2 | 250 | 710.00 | 4 | 108 | 312.12 | |
17/01/2024 | 5 | 500 | 1,420.00 | 1 | 83 | 237.38 | |
18/01/2024 | 1 | 1 | 2.84 | 3 | 501 | 1,437.87 | |
19/01/2024 | 3 | 188 | 537.68 | 4 | 250 | 725.00 | |
22/01/2024 | 4 | 750 | 2,227.50 | ||||
23/01/2024 | 36 | 6,500 | 28,535.00 | ||||
24/01/2024 | 38 | 5,726 | 30,004.24 | ||||
25/01/2024 | 17 | 2,000 | 8,960.00 | 8 | 994 | 4,622.10 | |
26/01/2024 | 6 | 750 | 3,232.50 | 3 | 402 | 1,776.84 | |
29/01/2024 | 8 | 750 | 3,285.00 | 7 | 604 | 2,742.16 | |
30/01/2024 | 4 | 463 | 2,046.46 | 3 | 750 | 3,367.50 | |
31/01/2024 | 6 | 1,037 | 4,490.21 | 2 | 500 | 2,190.00 | |
01/02/2024 | 12 | 1,000 | 4,260.00 | ||||
02/02/2024 | 6 | 750 | 3,157.50 | 2 | 250 | 1,090.00 | |
05/02/2024 | 7 | 500 | 2,100.00 | 5 | 501 | 2,134.26 | |
06/02/2024 | 7 | 660 | 2,831.40 | 4 | 500 | 2,200.00 | |
07/02/2024 | 5 | 395 | 1,666.90 | 3 | 501 | 2,169.33 | |
08/02/2024 | 10 | 1,274 | 5,287.10 | 9 | 815 | 3,423.00 | |
09/02/2024 | 4 | 267 | 1,148.10 | 5 | 686 | 3,018.40 | |
12/02/2024 | 3 | 503 | 2,213.20 | 2 | 497 | 2,211.65 | |
13/02/2024 | 4 | 731 | 3,135.99 | 1 | 1 | 4.43 | |
14/02/2024 | 5 | 850 | 3,638.00 | 3 | 376 | 1,650.64 | |
15/02/2024 | 2 | 399 | 1,687.77 | ||||
16/02/2024 | 1 | 250 | 1,075.00 | 13 | 2,123 | 9,426.12 | |
19/02/2024 | 3 | 250 | 1,100.00 | 1 | 250 | 1,125.00 | |
20/02/2024 | 6 | 950 | 4,284.50 | 6 | 1,250 | 5,700.00 | |
21/02/2024 | 22 | 1,877 | 8,859.44 | ||||
22/02/2024 | 14 | 1,623 | 8,098.77 | ||||
23/02/2024 | 12 | 1,250 | 6,287.50 | ||||
26/02/2024 | 8 | 1,250 | 6,075.00 | 2 | 456 | 2,252.64 | |
27/02/2024 | 7 | 751 | 3,717.45 | 17 | 2,244 | 11,264.88 | |
28/02/2024 | 3 | 500 | 2,510.00 | 25 | 2,001 | 10,145.07 | |
29/02/2024 | 7 | 1,001 | 4,984.98 | 15 | 999 | 5,094.90 | |
01/03/2024 | 4 | 1,000 | 5,020.00 | 21 | 3,274 | 16,992.06 | |
04/03/2024 | 27 | 1,748 | 8,477.80 | 7 | 782 | 3,831.80 | |
05/03/2024 | 1 | 5 | 24.70 | 15 | 2,718 | 13,617.18 | |
06/03/2024 | 16 | 1,750 | 8,925.00 | ||||
07/03/2024 | 8 | 831 | 4,188.24 | 3 | 144 | 740.16 | |
08/03/2024 | 27 | 4,998 | 22,840.86 | 9 | 988 | 4,544.80 | |
11/03/2024 | 10 | 1,940 | 8,749.40 | 8 | 689 | 3,128.06 | |
12/03/2024 | 5 | 651 | 2,942.52 | 4 | 498 | 2,280.84 | |
13/03/2024 | 6 | 950 | 4,294.00 | 5 | 514 | 2,343.84 | |
14/03/2024 | 13 | 2,576 | 11,257.12 | 8 | 702 | 3,130.92 | |
15/03/2024 | 28 | 4,721 | 15,248.83 | ||||
18/03/2024 | 11 | 2,500 | 8,250.00 | ||||
19/03/2024 | 15 | 3,100 | 9,486.00 | ||||
20/03/2024 | 11 | 2,750 | 7,975.00 | ||||
21/03/2024 | 8 | 1,272 | 3,739.68 | ||||
22/03/2024 | 10 | 1,978 | 5,657.08 | ||||
25/03/2024 | 7 | 410 | 1,271.00 | ||||
26/03/2024 | 3 | 97 | 300.70 | ||||
27/03/2024 | 3 | 252 | 806.40 | ||||
28/03/2024 | 2 | 498 | 1,628.46 | ||||
02/04/2024 | 2 | 500 | 1,635.00 | ||||
03/04/2024 | 2 | 500 | 1,610.00 | ||||
04/04/2024 | 1 | 36 | 118.80 | ||||
05/04/2024 | 1 | 250 | 835.00 | ||||
08/04/2024 | 2 | 250 | 850.00 | ||||
09/04/2024 | 1 | 250 | 850.00 | ||||
10/04/2024 | 3 | 110 | 374.00 | ||||
11/04/2024 | 2 | 390 | 1,337.70 | ||||
12/04/2024 | 4 | 500 | 1,800.00 | ||||
15/04/2024 | 3 | 456 | 1,673.52 | ||||
16/04/2024 | 7 | 664 | 2,529.84 | 2 | 500 | 1,965.00 | |
17/04/2024 | 3 | 250 | 975.00 | 3 | 699 | 2,775.03 | |
18/04/2024 | 1 | 46 | 185.84 | 4 | 301 | 1,219.05 | |
19/04/2024 | 9 | 1,318 | 5,496.06 | ||||
22/04/2024 | 21 | 6,943 | 26,730.55 | 17 | 2,250 | 8,775.00 | |
23/04/2024 | 3 | 199 | 754.21 | 6 | 750 | 2,887.50 | |
24/04/2024 | 9 | 2,048 | 7,864.32 | 11 | 2,250 | 9,022.50 | |
25/04/2024 | 17 | 45,000 | 13,950.00 | ||||
26/04/2024 | 53 | 110,000 | 42,900.00 | ||||
29/04/2024 | 14 | 6,518 | 2,542.02 | 7 | 5,000 | 2,100.00 | |
30/04/2024 | 23 | 17,982 | 6,653.34 | 10 | 4,000 | 1,560.00 | |
02/05/2024 | 21 | 16,355 | 6,214.90 | 7 | 6,000 | 2,520.00 | |
03/05/2024 | 1 | 1,000 | 390.00 | 1 | 1,000 | 400.00 | |
06/05/2024 | 1 | 1,000 | 400.00 | 4 | 4,000 | 1,680.00 | |
07/05/2024 | 5 | 4,000 | 2,000.00 | 48 | 32,792 | 17,051.84 | |
08/05/2024 | 5 | 4,000 | 2,840.00 | 74 | 44,208 | 32,713.92 | |
09/05/2024 | 59 | 24,740 | 20,039.40 | 31 | 14,412 | 12,394.32 | |
10/05/2024 | 16 | 11,900 | 7,735.00 | 34 | 21,180 | 16,308.60 | |
13/05/2024 | 22 | 11,700 | 8,892.00 | 14 | 8,000 | 6,320.00 | |
14/05/2024 | 8 | 6,000 | 4,620.00 | 25 | 13,000 | 10,530.00 | |
15/05/2024 | 47 | 27,593 | 28,420.79 | ||||
16/05/2024 | 30 | 16,406 | 15,913.82 | 18 | 11,000 | 11,550.00 | |
17/05/2024 | 7 | 7,000 | 6,650.00 | 5 | 1,227 | 1,202.46 | |
20/05/2024 | 19 | 10,094 | 9,387.42 | 9 | 3,984 | 3,784.80 | |
21/05/2024 | 17 | 9,700 | 8,827.00 | 9 | 4,625 | 4,301.25 | |
22/05/2024 | 9 | 5,000 | 4,550.00 | 7 | 2,274 | 2,092.08 | |
23/05/2024 | 6 | 5,000 | 4,350.00 | 1 | 25 | 22.75 | |
24/05/2024 | 11 | 4,004 | 3,323.32 | ||||
27/05/2024 | 12 | 5,996 | 4,916.72 | ||||
28/05/2024 | 10 | 6,000 | 4,680.00 | ||||
29/05/2024 | 10 | 3,428 | 2,639.56 | 4 | 3,000 | 2,370.00 | |
30/05/2024 | 21 | 13,952 | 10,045.44 | ||||
31/05/2024 | 8 | 4,620 | 3,095.40 | ||||
03/06/2024 | 10 | 4,000 | 3,240.00 | ||||
04/06/2024 | 41 | 24,165 | 23,681.70 | ||||
05/06/2024 | 7 | 4,915 | 5,603.10 | ||||
06/06/2024 | 11 | 8,000 | 7,520.00 | 2 | 165 | 181.50 | |
07/06/2024 | 2 | 1,000 | 920.00 | ||||
10/06/2024 | 13 | 10,000 | 8,600.00 | 6 | 1,000 | 880.00 | |
11/06/2024 | 9 | 4,500 | 3,780.00 | ||||
12/06/2024 | 7 | 4,001 | 3,280.82 | 4 | 3,001 | 2,520.84 | |
13/06/2024 | 18 | 7,866 | 6,371.46 | 1 | 424 | 360.40 | |
14/06/2024 | 27 | 22,134 | 15,493.80 | 31 | 4,587 | 3,256.77 | |
17/06/2024 | 13 | 9,969 | 6,778.92 | 13 | 5,543 | 4,046.39 | |
18/06/2024 | 16 | 4,300 | 3,010.00 | ||||
19/06/2024 | 7 | 1,774 | 1,224.06 | ||||
20/06/2024 | 5 | 1,226 | 858.20 | 8 | 4,800 | 3,552.00 | |
24/06/2024 | 2 | 500 | 380.00 | 2 | 770 | 592.90 | |
25/06/2024 | 12 | 5,000 | 3,700.00 | 5 | 398 | 302.48 | |
26/06/2024 | 11 | 4,019 | 2,893.68 | 2 | 930 | 669.60 | |
27/06/2024 | 3 | 1,001 | 710.71 | 1 | 1 | 0.72 | |
28/06/2024 | 7 | 4,981 | 3,486.70 | ||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718435279/en/
Contacts:
ACTICOR BIOTECH
Gilles AVENARD, MD
CEO and Founder
gilles.avenard@acticor-biotech.com
T.: +33 (0)6 76 23 38 13
Sophie BINAY, PhD
General Manager and CSO
Sophie.binay@acticor-biotech.com
T.: +33 (0)6 76 23 38 13
NewCap
Mathilde BOHIN
Investor Relations
acticor@newcap.eu
T.: +33 (0)1 44 71 94 95
NewCap
Arthur ROUILLÉ
Media Relations
acticor@newcap.eu
T.: +33 (0)1 44 71 00 15
